Drug Trial Radar · NCT00068029
Pegvisomant And Sandostatin LAR Combination Study
Last checked: Nov 20, 2026Latest source record: Apr 7, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Oct 2003
Primary completion
Not stated
Study completion May 2006
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 5, 2003
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Conditions
- Acromegaly
Interventions
Pegvisomant/ Sandostatin LARDrug
Sandostatin LARDrug
PegvisomantDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects experiencing treatment-emergent adverse events across the duration fo the study
Locations
33 sites in 12 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Chapel Hill, North Carolina
Pfizer Investigational Site
Charlottesville, Virginia
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
Fitzroy, Victoria, Australia
Pfizer Investigational Site
Fizroy, Victoria, Australia
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montpellier, France
Pfizer Investigational Site
Nice, France
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Dresden, Germany
Pfizer Investigational Site
Hanover, Germany
Pfizer Investigational Site
Genova, Italy
Pfizer Investigational Site
Messina, Italy
Pfizer Investigational Site
Milan, Italy
Pfizer Investigational Site
Torino, Italy
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Col La Raza, Mexico DF, Mexico
Pfizer Investigational Site
Nijmegen, Netherlands
Pfizer Investigational Site
Oslo, Norway
Pfizer Investigational Site
L'Hospitalet de Llobregat, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Leeds, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
Manchester, United Kingdom
Pfizer Investigational Site
Oxford, United Kingdom
Pfizer Investigational Site
Belfast, Antrim, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.